Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo
Sign Up to like & getrecommendations! Published in 2018 at "Pharmaceuticals"
DOI: 10.3390/ph11040132
Abstract: Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with 177Lu has been used in clinical trials for radioimmunotherapy (RIT) of… read more here.
Keywords: evaluation radiolabeled; dota scn; cg250; vitro vivo ... See more keywords